Suggestions
Danielle Ciofani
Strategy & Business Development Leader - Genomics | Clinical Data | Research & RWE
Danielle Ciofani is the Senior Director of Data Strategy and Business Development at the Data Sciences Platform (DSP) of the Broad Institute of MIT and Harvard, a position she has held since July 2019. In this role, she focuses on empowering health through data by developing strategies that leverage data for better health outcomes and facilitating precision health initiatives.
Professional Background
Ciofani has an extensive background in data strategy and analytics. Prior to her current role, she served as the Director of Data Strategy & Alliances at the same institute from October 2017 to July 2019. She also held positions at Optum Analytics, where she was the Director of Data Strategy and Market Strategy from 2015 to 2017, and worked at Humedica in various clinical data analytics roles from 2012 to 2015. Additionally, she has experience as an Executive in Residence at .406 Ventures and worked as an EMR Interface Architect at Accenture.
Education
Danielle Ciofani earned her Bachelor of Science in Engineering (BSE) in Biomedical Engineering and Spanish from Case Western Reserve University, graduating in 2008.
Contributions and Vision
Ciofani has been vocal about the importance of data democratization in healthcare, advocating for the integration of genomic data with clinical records to enhance health outcomes. She emphasizes the need for compliance with privacy laws while developing data-centric policies to ensure secure data usage. Her insights and leadership in data strategy are crucial for advancing the goals of the Broad Institute in the realm of precision medicine and population health.123
Highlights
Our genetics play a significant role in how we experience disease and whether or not a therapy will have an intended effect. Yet still, the way we diagnose and treat diseases that affect most people - for example, cardiovascular disease or type II diabetes - do not include genetic factors. Precision medicine is still an elusive concept largely restricted to cancer and rare disease.
We are now in the era of million-person scale biobanks such as #AllofUs and #EmiratiGenomeProgram, providing enough statistical power to draw conclusions on how to predict genetic risk for common diseases, and how to predict which patient will respond best to a given treatment. Importantly, diverse representation of the global population is key to building #responsibleAI for this new class of #digitaldiagnostics.
This week at #arabhealth2024, in the presence of #UAE Minister of Health - H.E. Abdul Rahman bin Mohammad Al Owais, Chairman Department of Health - H.E. Mansoor Al Mansoori and Director General Dubai Health Authority - H.E. Awadh Seghayer Al Ketbi, we announced our collaboration with M42 Health, Microsoft, and International Center for Genetic Disease to bring M42's Global Life Sciences platform to the community. This platform will vastly accelerate clinical impact to patients within the UAE and inform genomic research around the world.
The foundational building block for this platform will be Terra Bio on #Azure. Terra accelerates global impact of biomedical data by enabling over 65,000 researchers to analyze biomedical data and collaborate around the world, while ensuring data is secure and protected. By serving as the Trusted Research Environment for M42's biomedical research data, Terra on Azure will accelerate global R&D adoption of underrepresented populations in research, and catalyze a new era of genomics-powered diagnostics and medicine in the Middle East.
Thank you to M42 Health, particularly M42 leadership Ashish Ipe Koshy and Hasan Jasem Al Nowais, for hosting an exciting panel discussion at Arab Health this week where we announced this collaboration. Thank you also to co-panelists Elena Bonfiglioli, Junaid Bajwa, Mohammed Al Hadad, and host Amandeep Bhangu for an invigorating discussion. I learned grace under pressure from our communications and event teams Benjamin Schroeder, Magdalena Stepien, Bonny Lawrie and David Cameron. Finally, thank you to Alireza Haghighi, M.D., D.Phil., FACMG and International Center for Genetic Disease for your continued support in collaboration with Department of Health Abu Dhabi to advance life sciences.
Read more from the announcement: https://lnkd.in/gFp6ZKSy
Looking forward to the next wave of supporting biomedical research with partners Verily Life Sciences and Microsoft https://lnkd.in/eZxarET
